Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma ; day:19 ; month:06 ; year:2021 ; extent:12
Advanced therapeutics ; (19.06.2021) (gesamt 12)
- Urheber
-
Walter, Bianca
Canjuga, Denis
Yüz, Simge G.
Ghosh, Michael
Bozko, Przemyslaw
Przystal, Justyna M.
Govindarajan, Parameswari
Anderle, Nicole
Keller, Anna‐Lena
Tatagiba, Marcos
Schenke‐Layland, Katja
Rammensee, Hans‐Georg
Stevanovic, Stefan
Malek, Nisar P.
Schmees, Christian
Tabatabai, Ghazaleh
- DOI
-
10.1002/adtp.202100078
- URN
-
urn:nbn:de:101:1-2021081115213020243307
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Walter, Bianca
- Canjuga, Denis
- Yüz, Simge G.
- Ghosh, Michael
- Bozko, Przemyslaw
- Przystal, Justyna M.
- Govindarajan, Parameswari
- Anderle, Nicole
- Keller, Anna‐Lena
- Tatagiba, Marcos
- Schenke‐Layland, Katja
- Rammensee, Hans‐Georg
- Stevanovic, Stefan
- Malek, Nisar P.
- Schmees, Christian
- Tabatabai, Ghazaleh
Ähnliche Objekte (12)
Understanding, inducing and exploiting actionable vulnerabilities in experimental glioma
Roadmap toward subtype-specific vulnerabilities in adult glioma
Targeting the glioma associated microenvironment in experimental glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
Vulnerabilities
Glioma: experimental models and reality
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma
Fiscal-financial vulnerabilities
Understanding, inducing and exploiting actionable vulnerabilities in experimental glioma
Roadmap toward subtype-specific vulnerabilities in adult glioma
Targeting the glioma associated microenvironment in experimental glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
Vulnerabilities
Glioma: experimental models and reality
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma
Fiscal-financial vulnerabilities
Understanding, inducing and exploiting actionable vulnerabilities in experimental glioma
Roadmap toward subtype-specific vulnerabilities in adult glioma
Targeting the glioma associated microenvironment in experimental glioma
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
Vulnerabilities
Glioma: experimental models and reality
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer
Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes
Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma